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a b s t r a c t
The natural compound, curcumin (CUR), possesses several pharmacological properties, including
p300-speciﬁc histone acetyltransferase (HAT) inhibitory activity. In our previous study, we demonstrated
that CUR could prevent the development of cardiac hypertrophy by inhibiting p300-HAT activity. Other
major curcuminoids isolated from Curcuma longa including demethoxycurcumin (DMC) and bisdeme-
thoxycurcumin (BDMC) are structural analogs of CUR. In present study, we ﬁrst conﬁrmed the effect of
these three curcuminoid analogs on p300-HAT activity and cardiomyocyte hypertrophy.
Our results showed that DMC and BDMC inhibited p300-HAT activity and cardiomyocyte hypertrophy
to almost the same extent as CUR. As the three compounds have structural differences in methoxy groups
at the 3-position of their phenol rings, our results suggest that these methoxy groups are not involved in
the inhibitory effects on p300-HAT activity and cardiac hypertrophy. These ﬁndings provide useful
insights into the structureeactivity relationship and biological activity of curcuminoids for p300-HAT
activity and cardiomyocyte hypertrophy.
© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
As morbidity and mortality rates for heart failure remain high in
developed countries, new therapies for heart failure are required to
reduce these rates and the cost of their associated medical care. The
heart works as a pump, circulating blood via its rhythmic
contractions. The cardiomyocytes that constitutes the heart have
the ability to proliferate in the fetal stage but lose this ability after
birth. Various kinds of hemodynamic stress that affect the heart,
such as hypertension and myocardial infarction, lead to car-
diomyocyte hypertrophy, in an attempt to maintain cardiac
function. However, this compensatory response of cardiomyocytes
degrades and cardiac function diminishes, leading to heart
failure.1,2 The established drugs for heart failure, such as b-blockers,
angiotensin-converting enzyme inhibitors, and angiotensin II
receptor blockers, target neurohumoral factors and receptors on
the cell membrane.3,4 However, even with the use of these drugs,
patients with severe heart failure have a short life expectancy,5 and
new therapies for heart failure are urgently required.
Signals of hemodynamic stress ﬁnally reach the common
nuclear pathways of cardiomyocytes and activated a transcriptional
coactivator, p300. The histone acetyltransferase (HAT) activity of
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p300 has been found to play a crucial role in the progression of
cardiac hypertrophy and the development of heart failure. There-
fore, HAT activity of p300 is a potential new therapeutic target for
heart failure.6,7 Balasubramanyam et al. reported that curcumin
(CUR), derived from the plant Curcuma longa, is a speciﬁc inhibitor
of p300-HAT activity.8 A polyphenol, CUR has long been used in
traditional Ayurvedic and Chinese herbal medicines and as a spice
in Indian and Chinese food. In previous studies, we demonstrated
that CUR signiﬁcantly attenuated cardiomyocyte hypertrophy,
diminished cardiac dysfunction, and prevented the development of
heart failure in two different heart failure animal models.9,10 These
ﬁndings suggested that CUR, an inexpensive and safe polyphenol,
might serve as a new therapy for heart failure.
CUR (1,7-bis-(4-hydroxy-3-methoxyphenyl)-hepta-1,6-diene-
3,5-dione) is a natural compound made up of 2 hydroxyl groups, 2
phenyl groups, 2 methoxy groups, and a b-diketone moiety. The
b-diketone moiety undergoes ketoeenol tautomerism, and CUR
often occurs in an enol form when a liquid state.11,12 In addition to
CUR, curcuminoids include demethoxycurcumin (DMC), which has
a single methoxy group, and bisdemethoxycurcumin (BDMC),
which has no methoxy groups (Fig. 1). Typical commerically
available curcuminoids consist of 77% CUR, 17% DMC, and 3%
BDMC.13 Like CUR, DMC and BDMC also have various physiological
activities, such as antioxidant,14e16 anticancer,17e19 and anti-
inﬂammatoryactivities.16,17,19 However, studies have revealed that
the potency of these activities differs among CUR, DMC, and BDMC.
Nevertheless, these studies have not examined the effect of
different curcuminoids on p300 HAT activity and hypertrophic
response. In this study, we performed a comparative study of




CUR, DMC, and BDMC were purchased from Nagara Science
Corporation (Gifu, Japan). These curcuminoids were prepared as
100 mM stock solutions in dimethyl sulfoxide (DMSO) and stored
at 20 C.
Measurement of p300 HAT activity in vitro
Gene fragments containing the catalytic domain of human
p300-HAT (amino acids 1284e1673) were subcloned into
pGEX-6p1 (GE Healthcare, USA). Glutathione-S-transferase (GST)
fusion protein was prepared from the BL21 strain of E. coli and
puriﬁed by afﬁnity chromatography using glutathione Sepharose
4B. Five micrograms of core histones from Calf Thymuscarf
(Worthington, USA) was incubated in HAT assay buffer (50 mM
TriseHCl of pH 8.0, 10% (v/v) glycerol, 1 mM dithiothreitol, and
0.1 mM EDTA-Na2 of pH 8.0) at room temperature for 30 min
with or without the recombinant p300-HAT domain in the
presence or absence of curcuminoids. Then, acetyl-CoA was
added and the mixtures were further incubated for another
30 min. The reaction mixture was subjected to SDS-PAGE
followed by Western immunoblotting using rabbit polyclonal
anti-acetyl-H3K9 antibody and rabbit polyclonal anti-histone H3
antibody (Cell Signaling Technology, USA). The signals were
detected with a C-DiGit Chemiluminescent Western Blot Scanner
(LI-COR, USA). The ratio of acetylated histone H3K9 to total
histone H3 was quantiﬁed using Image Studio LITE software
(LI-COR, USA).
Cell culture and histone acetylation analysis
All procedures were performed in conformity with the Guide for
the Care and Use of Laboratory Animals of the University of Shi-
zuoka and the protocol was approved by the Institutional Animal
Care and Use Committee of the University of Shizuoka. Isolation of
primary neonatal rat cardiomyocytes has been previously
described.20 Cardiomyocytes were pretreated with either 10 mM
curcuminoids or DMSO as its solvent for 2 h, and then stimulated
with 30 mM phenylephrine (PE) or salt saline (SS) as negative
control. Forty-eight hours after incubation, the core histones from
these cells were isolated by acid extraction as previously
described.21 The samples were subjected to SDS-PAGE, followed by
western blotting.
RNA extraction and quantiﬁed real-time PCR (RT-PCR)
Total RNA from cardiomyocytes was isolated, reverse-
transcribed, and ampliﬁed as previously described.22 Brieﬂy, total
RNA from cardiomyocytes was isolated using TRI Reagent (MRC Inc,
USA) and subjected to reverse transcription using a ReverTra Ace
qPCR RT Master Mix (TOYOBO, Japan). RT-PCR was performed as
previously described.22 An ABI 7500 real-time PCR system (Applied
Biosystems, USA) was used with SYBR Green (TOYOBO, Japan) for
the purpose. The primer pairs of atrial natriuretic factor (ANF),
brain natriuretic peptide (BNP) and 18S have been previously
described.23e25 Values were normalized to 18S and represented
using the DCt method.
Measurement of cardiomyocyte surface area
Cardiomyocytes cultured in ﬂask-style chambers with glass
slides (Thermo, USA) were ﬁxed in 3.7% paraformaldehyde and
stained with anti-b-myosin heavy chain (b-MHC) antibody (Leica,
USA) as previously described.26 Then, the surface areas of 50
cardiomyocytes were measured semiautomatically using an image
analyzer (Image J v1.46).
Statistical analysis
Data are presented as the mean ± standard error of the mean
(SEM). Statistical comparisons were performed by analysis of
variance (ANOVA), followed by Tukey's multiple-comparison test;
p < 0.05 was considered statistically signiﬁcant.
Fig. 1. Structure of curcuminoids. A, curcumin (CUR). B, demethoxycurcumin (DMC).
C, bisdemethoxycurcumin (BDMC).
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Results
To evaluate the inhibitory effect of curcuminoids against
p300-HAT activity, an in vitro HAT assay was performed using
recombinant p300-HAT domain with 20 and 60 mM of CUR, DMC,
and BDMC, and after 2 h, samples were subjected to immuno-
blotting with the antibody against acetylated forms of histone
H3K9 or total histone 3 (Fig. 2A). The results showed that p300-
induced acetylation of H3K9 was dose-dependently suppressed
by CUR, DMC, and BDMC treatments. High dose (60 mM) of DMC
and BDMC signiﬁcantly inhibited the acetylation of H3K9, and to
the same extent as those of CUR. These ﬁndings indicate that these
three curcuminoids have similar inhibitory effects on p300 HAT
activity in vitro.
Next, to examine the effect of curcuminoids on PE-induced
histone acetylation in primary cardiomyocytes prepared from
neonatal rats, the cells were stimulated with saline or 30 mM PE, an
a1-adrenergic agonist, in the presence or absence of curcuminoids
(10 mM), and after 48 h, protein extracts from these cells were
subjected to immunoblotting with the antibody against acetylated
forms of H3K9 (Fig. 3A). The results showed that DMC and BDMC
signiﬁcantly repressed PE-induced acetylation of H3K9 to the same
extent as CUR although CUR, DMC, and BDMC did not affect the
basal level of H3K9-acetylation in cardiomyocytes.
Finally, to examine the effects of curcuminoids on hypertrophic
responses in primary cardiomyocytes, these cells were stimulated
with saline or 30 mMPE in the presence or absence of curcuminoids
(10 mM), and after 48 h, the cells were stained with an antibody
against cardiac MHC (Fig. 4A). The results showed that CUR, DMC,
and BDMC treatments did not change morphology of car-
diomyocyte, such as cell surface are and myoﬁbrillar organization.
CUR, DMC, and BDMC signiﬁcantly inhibited the PE-induced
increase in myocardial cell-surface area to a similar extent
(Fig. 4B). After that, the effects of curcumioids on PE-induced
expression of ANF and BNP were examined using real-time
RT-PCR. The upregulated expression of them is a well-established
marker of myocardial cell hypertrophy. DMC and BDMC signiﬁ-
cantly inhibited the PE-induced up-regulation of the expression of
endogenous ANF (Fig. 4C) and BNP (Fig. 4D) mRNAs, and to the
same extent as CUR.
Discussion
Our previous studies have shown both that the HAT activity of
p300 is a pharmacological target for heart failure therapy, and that
CUR is an inhibitor of the HAT activity of p300. In the present study,
we examined the structureeactivity relationship of CUR in p300
HAT activity. Three curcuminoids with different structures were
Fig. 2. Curcuminoids inhibit p300-HAT activity in vitro. A, In vitro HAT assays were
performed with a recombinant p300 HAT domain in the presence of CUR, DMC, and
BDMC (20, 60 mM) using core histones (2 mg). Acetylated histone H3K9 and total his-
tone H3 were detected by western blotting. B, The ratio of acetylated histone H3K9 to
total histone H3 was quantiﬁed by densitometry with the use of Image Studio LITE
software (LI-COR). The data are shown as mean ± SEM. All data were based on three
independent experiments.
Fig. 3. Curcuminoids prevent phenylephrine-induced acetylation of histone H3K9 in
cardiomyocytes. A, Cultured cardiomyocytes were treated with CUR, DMC, and BDMC
(10 mM) in the presence or absence of PE (30 mM) for 48 h. Histone extracts from these
cells were subjected to western blotting for acetylated histone H3K9 or total histone
H3 as indicated. B, The amounts of acetylated H3K9 and total H3 were quantiﬁed. The
data are shown as mean ± SEM. All data were based on three independent
experiments.
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Fig. 4. Curcuminoids attenuate phenylephrine-induced hypertrophic responses in cardiomyocytes. A, Cardiomyocytes were incubated with CUR, DMC, and BDMC (10 mM) in the
presence or absence of PE (30 mM) for 48 h. These cells were subjected to immunocytochemistry using the primary antibody against b-MHC, followed by staining with a secondary
antibody conjugated with peroxidase (brown signals). B, The cell surface areas were quantiﬁed using ImageJ software. The data were based on three independent experiments and
are presented as mean ± SEM. Scale bar indicates 20 mm. C and D, Cultured cardiomyocytes were stimulated with saline or PE (30 mM) in the presence of CUR, DMC, and BDMC
(10 mM) for 48 h. Total RNA from these cardiomyocytes was subjected to real-time RT-PCR. The amounts of transcripts for the ANF (C) and BNP (D) genes were normalized by that of
the 18S gene. The data were based on three independent experiments, each carried out in duplicate, and shown as mean ± SEM.
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used to examine the effect of CUR on the inhibition of p300 HAT
activity and hypertrophic responses. The results revealed no
differences between CUR, DMC, and BDMC in terms of their inhi-
bition of p300 HAT activity and hypertrophic responses. As these
curcuminoids differ in the presence of absence of methoxy groups
at the 3 position of their phenyl groups at either end of their
molecules, it is safe to assume that these methoxy groups are not
associated with the inhibition of p300-HAT activity or with the
inhibition of hypertrophic responses.
Numerous studies have examined differences in the physiologic
activity of these curcuminoids. A typical physiological activity of
CUR is antioxidant activity. The structureeactivity relationship of
curcuminoids on antioxidant activity has been demonstrated.14e16
Tetrahydrocurcumin, which hydrogenated the two double bonds
conjugated with b-diketone of curcumin, was showed higher or
comparable scavenging potency as curcumin toward all of the
tested free radicals.15 The unshared electron pair on the oxygen
atoms in the hydroxyl group attached to both of the CUR phenyl
groups readily delocalizes, so these hydroxyl groups are associated
with antioxidant activity.16 5-chloro CUR, a CUR derivative with a
chlorine atom replacing one of the oxygen atoms on b-diketone
moiety, has stronger antioxidant activity than CUR or ascorbic
acid.27 These ﬁndings suggest that the antioxidant activity of CUR is
attributable to the hydroxyl group attached to each phenyl group
and the b-diketone moiety.
Differences have also been found between the three compounds
in their anti-cancer and anti-inﬂammation activity. In an experi-
ment inducing skin cancer in mice with the carcinogen 12-O-
tetradecanoylphorbol-13-acetate (TPA), CUR and DMC inhibited
carcinogenesis to the same extent, while BDMC had weaker
inhibitory activity.28 In addition, BDMC has been shown to inhibit
cancer cell invasion to the same or a greater extent than DMC, but
CUR inhibited cancer cell invasion to a lesser extent.18 The Studies
that have been done shown no differences in the ability of CUR,
DMC, and BDMC to inhibit the growth of various types of cultured
cancer cells. The inhibition of particular processes, such as carci-
nogenesis, proliferation, or metastasis, differs depending on the
form of the curcuminoid, so the appropriate curcuminoid for cancer
treatment may differ depending on the process that is being tar-
geted.19 On the other hand, CUR, DMC, and BDMC have also been
shown to inhibit TPA-induced inﬂammation in the ears of mice to
the same extent.28 Nuclear factor-kappa B (NF-kB), which regulates
various cytokines and plays a crucial role in inﬂammation, is most
potently inhibited by CUR, followed by DMC, and then BDMC.18,19 In
summary, the 30 methoxy groups of CUR are not associated with
inhibition of p300 HAT activity, or inhibition of cardiomyocyte
hypertrophy, suggesting the therapeutic effect of curcumin on
heart failure may dependent p300-speciﬁc HAT inhibition.
p300-speciﬁc HAT inhibitors other than CUR have also been
previously found. C646 was identiﬁed by in silico screening based
on protein conformations.29 C646 competes with acetyl-CoA to
bind to p300, thus inhibiting its activity. CUR is unique in com-
parison to other HAT inhibitors. It binds to p300 at sites other than
its sites of catalytic domain, altering the conformation of its HAT
domain and inhibiting the binding of p300 to acetyl-CoA and
substrates.8 Thus, it is difﬁcult to determine the structureeactivity
relationship of CUR based on conformation of the HAT domain. CUR
is a b-diketone, and the b-diketone moiety of CUR results in its
ketoeenol tautomerism. Based on the results of the present study,
the ketoeenol tautomerism of curcumin, but not the methoxy
group at the 3 position of the CUR phenyl group, may be associated
with binding to the HAT domain of p300 and conformational
changes at its sites of catalytic domain. These ﬁndings should be
helpful for determining the structureeactivity relationship of CUR
and for developing a more speciﬁc and effective CUR derivative.
Further experiments would be required to clarify whether
b-diketone moiety of curcumin associate with the inhibition of
p300-HAT activity and hypertrophic responses.
CUR, DMC, and BDMC exhibit strong or weak physiologic
activity depending on the target molecule. The present study found
no differences in the inhibition of p300 HAT activity by CUR, DMC,
and BDMC or in the ability of those curcuminoids to inhibit
hypertrophic responses. Because numerous factors are associated
with the onset and progression of heart failure, further experiments
should be conducted with animal models to investigate the
differences between these curcuminoids. CUR has been found to be
effective in preventing cardiac hypertrophy and the development of
heart failure in animals, so CUR is expected to be applicable in
clinical settings as well.10,30e33 The present study has also revealed
that the methoxy groups of CUR are not associated with the
inhibition of p300 HAT activity, bringing us a step closer to eluci-
dating the mechanism by which CUR inhibits p300. Further studies
of the structureeactivity relationship of CUR may lead to the
development of novel therapies for heart failure.
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